RESEARCH - Subcutaneous injection of new formulation of Orencia (abatacept) comparable to IV

[Guest guest]

New Data Show That Subcutaneous Injection Of An Investigational

Formulation Of ORENCIA® Provided Similar Improvement Compared To

Intraveous Therapy

MedicalNewsToday.com

Article Date: 10 Nov 2010 - 3:00 PST

(NYSE:BMY) announced that new Phase III clinical data show that a

weekly subcutaneous injection of an investigational formulation of

ORENCIA® (abatacept), following a single intravenous (I.V.) loading

dose, provided an improvement in disease activity similar to the

improvement seen with monthly I.V. administration of ORENCIA in

patients with moderate to severe rheumatoid arthritis (RA).

Improvement in disease activity was measured using the ACR20 criteria

(a measurement of RA disease state improvement). The ACQUIRE

(Abatacept Comparison of Sub(Qu)cutaneous vs. Intravenous in

Inadequate Responders to Methotrexate) trial is a multinational study

involving 1,457 patients. ORENCIA has the potential to become the

first biologic agent to offer physicians and their appropriate RA

patients the flexibility to choose either weekly subcutaneous or

monthly I.V. administration. The ACQUIRE results will be presented on

November 10 at the American College of Rheumatology (ACR) Annual

Scientific Meeting, which is being held in Atlanta from November 6 to

11.

******************************************

Read the whole article here:

http://www.medicalnewstoday.com/articles/207275.php

Not an MD